Prostate Cancer News and Research

Latest Prostate Cancer News and Research

New Australian drug approvals subject to budget cuts

According to Health Minister Nicola Roxon’s statement to pharmaceutical company bosses, new medicines will no longer be subsidised unless budget savings can be found.

9 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

Debate continues regarding certain medical tests

News outlets report on how discussion continues to swirl around the use of the so-called "PSA velocity" test and mammography guidelines.

8 Mar 2011

Scientists develop innovative device to efficiently identify CTCs in blood

Circulating tumor cells, which play a crucial role in cancer metastasis, have been known to science for more than 100 years, and researchers have long endeavored to track and capture them.

8 Mar 2011

5a-reductase inhibitors for male health problems can affect sexual health

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

7 Mar 2011

How cancer impacts patients and their partners

Katarina Sjövall has studied partners of individuals with colorectal cancer, lung cancer, breast cancer or prostate cancer. The study shows that the number of diagnosed diseases among partners increased by 25 per cent after the cancer diagnosis.

4 Mar 2011

New, inexpensive method to accurately differentiate between benign and malignant breast tumors

Recent research by doctoral student Sevan Goenezen holds the promise of becoming a powerful new weapon in the fight against breast cancer. His complex computational research has led to a fast, inexpensive new method for using ultrasound and advanced algorithms to differentiate between benign and malignant tumors with a high degree of accuracy.

4 Mar 2011

Hemispherx, Chronix jointly file US patent application for CFS blood test

Chronix Biomedical announced today that it filed a provisional United States patent application jointly with Hemispherx Biopharma, Inc. on a blood test for Chronic Fatigue Syndrome.

4 Mar 2011

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Endo Pharmaceuticals announced that FORTESTA Gel – recently approved by the U.S. Food and Drug Administration for the treatment of low testosterone, or 'Low T' in adult males – is now available by prescription in pharmacies across the country.

3 Mar 2011

U-M scientists identify potential target to treat aggressive prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer. The target, a gene called SPINK1, could be to prostate cancer what HER2 has become for breast cancer.

3 Mar 2011

BigThink.com launches breakthroughs: Discussion highlighting cutting-edge cancer research

Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.

2 Mar 2011

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

GTx, Inc. today announced that the company and Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

2 Mar 2011

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

In 2010, Group drug sales grew 5.1% year-on-year - at constant currency - exceeding the objective set a year ago of 3.0% to 5.0%, fuelled notably by the sales of Specialty Care products throughout all the geographical regions where the Group operates.

2 Mar 2011

Robotic surgery offers better results than laparoscopic procedures for kidney disease

Robotic surgery offers the same or better results than minimally invasive laparoscopic procedures for treating kidney disease, and can potentially help more patients because it is not as difficult for surgeons to learn, according to a new study led by Henry Ford Hospital specialists.

2 Mar 2011

Robotic surgery offers favourable outcomes in patients with kidney disease

2 Mar 2011

Market demands shape health sector growth

The Wall Street Journal reports on how a string of recent acquisitions are being spurred by an increased demand for outpatient facilities and senior care. However, The Washington Post reports that some specific facilities — those that are doctor-owned, for instance — are sparking criticism.

1 Mar 2011

Sudden cessation of smoking may be symptom of lung cancer

Many longtime smokers quit spontaneously with little effort shortly before their lung cancer is diagnosed, leading some researchers to speculate that sudden cessation may be a symptom of lung cancer.

1 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Eigen ei-Nav|Artemis system for prostate biopsy installed at Smilow Comprehensive Prostate Cancer Center

As a world leader in the advancement of the detection and treatment of prostate cancer, the Smilow Comprehensive Prostate Cancer Center at NYU Langone Medical Center is the first medical facility in the Northeast to install ei-Nav|Artemis™, an innovative image guidance and navigation system for prostate biopsy that is manufactured by Eigen.

25 Feb 2011